Last Chance Anti-human Respiratory Syncytial Virus(rsv) Fusion Glycoprotein/rsv-f Neutralizing Antibody 45% Off - Today Only [eQdgXxch]

Anti-Human Respiratory Syncytial Virus (RSV) Fusion Glycoprotein/RSV-F Neutralizing Antibody

Introducing our highly effective Anti-Human Respiratory Syncytial Virus (RSV) Fusion Glycoprotein/RSV-F Neutralizing Antibody, designed to combat the most common etiological agent of acute lower respiratory tract disease in infants. This monoclonal antibody, derived from rabbits, offers robust reactivity against RSV and is a powerful tool for both microneutralization and ELISA applications. With its specific focus on the RSV-F protein, this antibody is a crucial component in the fight against this virus.

Product Properties and Specifications

Our RSV-F Neutralizing Antibody is characterized by its high purity and concentration, ensuring reliable and consistent results in various experiments. It is produced using recombinant RSV (A2) Fusion glycoprotein, providing a reliable source of antigen. This antibody is unconjugated, allowing for flexibility in its use. Key specifications include:

• Isotype: IgG
• Host: Rabbit
• Reactivity: RSV
• Applications: Microneutralization, ELISA
• Concentration: 1 mg/mL

The antibody is purified through Protein A Affinity Chromatography, ensuring a high level of purity. It is supplied in a 0.2 μm filtered solution in PBS, optimized for stability and compatibility with various laboratory techniques.

Practical Uses and Benefits

This Anti-Human RSV-F Neutralizing Antibody is an invaluable tool for researchers and healthcare professionals. Its applications in microneutralization and ELISA make it suitable for a wide range of studies, including virus detection, infection prevention, and vaccine development. The antibody's ability to neutralize RSV effectively can help mitigate the severity of respiratory infections, particularly in vulnerable populations such as infants. By utilizing this antibody, researchers can contribute to the development of new treatments and preventive strategies, ultimately leading to better health outcomes for those affected by RSV.